Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Plastic pollution poses a severe health crisis, infiltrating bodies with harmful chemicals, urging immediate action for ...

Panelists discuss the EMBER-3 trial, which evaluated single-agent oral selective estrogen receptor degrader (SERD) ...

HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for ...

Singer Jessie J. recently shared her breast cancer journey, highlighting the importance of early detection. Breast cancer, a disease where breast cell ...

"I thought I was too young to have cancer," Alexis Klimpl told Newsweek, adding: " "In my eyes, my breasts betrayed me." ...

At the same time, camizestrant and vepdegestrant are part of a crowded landscape of estrogen receptor degraders, and these studies raise more questions than they answer about when and how these newer ...

Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin–proteasome system. In this phase 3, open-label, randomized ...

Estrogen receptor α (ERα) is pivotal in gene regulation, particularly in estrogen-responsive cancers. However, the full-length molecular dynamic structure of ERα remains elusive. In this study, we ...